Cannabis is the most widely used illicit drug globally, and approximately 19.5% of cannabis users develop Cannabis Use Disorder (CUD), which is characterized by persistent impairment and an inability to cut down cannabis use.
Cannabis belongs to the Cannabaceae family and is classified under the genus Cannabis.
There are three primary species: Cannabis sativa, Cannabis indica, and Cannabis ruderalis.
Cannabis contains various chemical compounds, including cannabinoids.
The most well-known and psychoactive cannabinoid is delta-9-tetrahydrocannabinol (THC).
When consumed, THC binds to cannabinoid receptors in the brain, producing psychoactive effects such as euphoria, relaxation, altered perception, and increased appetite.
Cannabis has been used for medicinal purposes in many cultures.
It is believed to have potential therapeutic benefits for conditions like chronic pain, nausea and vomiting associated with chemotherapy, muscle spasms, epilepsy, and more.
Medicinal cannabis products are often prescribed or recommended in controlled and regulated settings.
Animal studies and human clinical trials have identified a potential new drug that could aid in the treatment of cannabis addiction.
The newly developed drug acts as an inhibitor of the cannabinoid receptor (CB1), which is responsible for the behavioral effects of cannabis.
The drug has demonstrated the ability to reduce the effects of cannabis without triggering withdrawal symptoms.
COMMENTS